STOCK TITAN

Eli Lilly & Co. - LLY STOCK NEWS

Welcome to our dedicated page for Eli Lilly & Co. news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Eli Lilly & Co. stock.

Eli Lilly and Company (NYSE: LLY), founded in 1876 by Colonel Eli Lilly, is a global leader in the pharmaceutical industry, headquartered in Indianapolis, Indiana. With operations in 18 countries and products sold in approximately 125 countries, Eli Lilly is dedicated to pioneering life-changing discoveries through innovative drug development. The company focuses on several therapeutic areas including neuroscience, cardiometabolic, cancer, and immunology.

Key products in Eli Lilly’s portfolio include Verzenio for cancer treatment; Jardiance, Trulicity, Humalog, Humulin, Mounjaro, and Zepbound for diabetes management; and Taltz and Olumiant for immunology. The company's recent financial performance has been robust, with Q1 2024 revenues increasing by 26% year-over-year to $8.77 billion, driven by strong sales of Mounjaro and Zepbound.

Eli Lilly continues to expand its manufacturing capabilities to meet growing demand, recently investing $5.3 billion in its Lebanon, Indiana site. This commitment supports the production of key therapies, particularly for chronic diseases like obesity and type 2 diabetes. The company’s innovative endeavors include the development of new treatments such as the once-weekly insulin efsitora alfa, which showed promising results in phase 3 trials for type 2 diabetes.

The company is also advancing its pipeline of oncology treatments with presentations of data on products like Verzenio, Retevmo, olomorasib, and imlunestrant at major medical conferences. Furthermore, Eli Lilly announced a major leadership change with Melissa Seymour joining as Executive Vice President of Global Quality, ensuring the sustained excellence of their product offerings.

Eli Lilly’s commitment to addressing significant health challenges is evident in its diverse product pipeline and ongoing clinical trials. The company remains focused on improving patient outcomes globally by harnessing advancements in biotechnology, chemistry, and genetic medicine.

Rhea-AI Summary
The FDA has issued a complete response letter for Eli Lilly's lebrikizumab biologic license application for the treatment of eczema. The letter cited findings from an inspection of a third-party manufacturing organization. However, the FDA stated no concerns about the clinical data package, safety, or label for lebrikizumab. Lilly remains confident in the drug's potential and will work to address the feedback.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
none
-
Rhea-AI Summary
FDA approves Jardiance to reduce risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
-
Rhea-AI Summary
Eli Lilly announces positive results from LIBRETTO-531 study on Retevmo for advanced thyroid cancer treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
none
Rhea-AI Summary
Eli Lilly and Company completes acquisition of Versanis Bio, expanding its portfolio with bimagrumab
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
-
Rhea-AI Summary
Eli Lilly completes acquisition of Sigilon Therapeutics, enabling research and development of cell therapies for type 1 diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
-
Rhea-AI Summary
Eli Lilly and Company has successfully completed its acquisition of DICE Therapeutics, expanding its immunology portfolio. The acquisition includes DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors for treating chronic diseases in immunology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
Rhea-AI Summary
Eli Lilly Q2 2023 revenue increased 28% to $8.31 billion, driven by volume growth and sale of rights for Baqsimi. EPS increased 86% to $1.95. Positive results in Alzheimer's and obesity studies. Acquisitions of DICE Therapeutics, Sigilon Therapeutics, and Versanis Bio announced.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.87%
Tags
-
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) announced topline results from the LIBRETTO-431 study, showing a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for Retevmo as an initial treatment for patients with RET fusion-positive advanced or metastatic non-small cell lung cancer (NSCLC). Adverse events observed were consistent with those identified across the previously reported Retevmo development program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
none
-
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) announces impressive results from phase 3 tirzepatide studies, with participants achieving up to 26.6% mean weight loss over 84-88 weeks. The overall safety profile of tirzepatide was similar to previously reported trials, with gastrointestinal-related adverse events being the most common.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags

FAQ

What is the current stock price of Eli Lilly & Co. (LLY)?

The current stock price of Eli Lilly & Co. (LLY) is $746.2 as of November 15, 2024.

What is the market cap of Eli Lilly & Co. (LLY)?

The market cap of Eli Lilly & Co. (LLY) is approximately 713.4B.

What are Eli Lilly's core business areas?

Eli Lilly focuses on neuroscience, cardiometabolic, cancer, and immunology.

What are some of Eli Lilly's key products?

Key products include Verzenio for cancer, Jardiance, Trulicity, Humalog, Humulin, Mounjaro, and Zepbound for diabetes, and Taltz and Olumiant for immunology.

How did Eli Lilly perform financially in Q1 2024?

Eli Lilly reported a 26% year-over-year increase in revenue to $8.77 billion, driven by strong sales of Mounjaro and Zepbound.

What recent investments has Eli Lilly made?

Eli Lilly has invested $5.3 billion to expand its manufacturing site in Lebanon, Indiana, supporting the production of treatments for chronic diseases like obesity and type 2 diabetes.

Who is the new Executive Vice President of Global Quality at Eli Lilly?

Melissa Seymour has been appointed as the new Executive Vice President of Global Quality, effective July 22, 2024.

What are some recent clinical trial results shared by Eli Lilly?

Eli Lilly shared positive results from trials for insulin efsitora alfa, Verzenio, Retevmo, olomorasib, and imlunestrant, showcasing their advancements in treatments for diabetes and cancer.

In how many countries does Eli Lilly operate?

Eli Lilly operates in 18 countries and its products are sold in approximately 125 countries.

What is the significance of Eli Lilly's recent investment in Lebanon, Indiana?

The investment will enhance production capacity for essential treatments like Zepbound and Mounjaro, aiming to meet the growing demand for these medicines.

What is the focus of Eli Lilly's ongoing research and development?

Eli Lilly's R&D focuses on innovative solutions for diabetes care, obesity, Alzheimer's disease, immune disorders, and cancer.

What are some common side effects of Eli Lilly's product Mounjaro?

Common side effects of Mounjaro include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach pain.

Eli Lilly & Co.

NYSE:LLY

LLY Rankings

LLY Stock Data

713.43B
950.41M
0.15%
83.46%
0.64%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
INDIANAPOLIS